A multicenter randomized Phase 2 trial called DURABLE showed maintenance therapy with durvalumab plus anlotinib improved outcomes versus durvalumab alone in extensive-stage small-cell lung cancer (ES-SCLC). The study tested a dual regimen intended to strengthen durability of checkpoint blockade in a disease area with limited long-term options. The report focuses on efficacy and biomarker profiles associated with the randomized comparison, with the maintenance strategy producing a favorable signal for the combination arm. The trial’s design and biomarker analyses are expected to inform future selection of patients most likely to benefit from anti-angiogenic pairing strategies. For ES-SCLC, the data contribute to the ongoing effort to convert initial responses into longer control periods, particularly through maintenance approaches rather than adding new lines of therapy after progression.